Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ (L-glutamine oral powder) to Military Personnel and Beneficiaries for Treatment of Sickle Cell DiseaseJuly 30, 2018 Read More
Emmaus Life Sciences Strengthens its Finance & Operations Leadership to Support Commercialization of Endari™July 26, 2018 Read More
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell DiseaseJuly 18, 2018 Read More
Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of DiverticulosisJuly 11, 2018 Read More
Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc.June 19, 2018 Read More
